New pill shows promise in early trial for Hard-to-Treat blood cancers
NCT ID NCT06137144
First seen Apr 30, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests a new oral drug called AZD3470 in people with certain blood cancers, including Hodgkin and non-Hodgkin lymphoma. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 161 adults and adolescents will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGDuarte, California, 91010, United States
-
Research Site
RECRUITINGMiami, Florida, 33136, United States
-
Research Site
WITHDRAWNAtlanta, Georgia, 30322, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02215, United States
-
Research Site
NOT_YET_RECRUITINGNew York, New York, 10016, United States
-
Research Site
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
WITHDRAWNAdelaide, 5000, Australia
-
Research Site
NOT_YET_RECRUITINGFitzroy, 3065, Australia
-
Research Site
RECRUITINGNedlands, 6009, Australia
-
Research Site
WITHDRAWNSouth Brisbane, 4101, Australia
-
Research Site
WITHDRAWNWaratah, 2298, Australia
-
Research Site
NOT_YET_RECRUITINGBeijing, 100191, China
-
Research Site
NOT_YET_RECRUITINGGuangzhou, 510060, China
-
Research Site
NOT_YET_RECRUITINGShanghai, 20032, China
-
Research Site
TERMINATEDCréteil, 94010, France
-
Research Site
RECRUITINGLille, 59000, France
-
Research Site
RECRUITINGPierre-Bénite, 69310, France
-
Research Site
RECRUITINGVillejuif, 94805, France
-
Research Site
NOT_YET_RECRUITINGBerlin, 12203, Germany
-
Research Site
RECRUITINGCologne, 50937, Germany
-
Research Site
NOT_YET_RECRUITINGErlangen, 91054, Germany
-
Research Site
NOT_YET_RECRUITINGWürzburg, 97080, Germany
-
Research Site
RECRUITINGAlessandria, 15100, Italy
-
Research Site
RECRUITINGBologna, 40138, Italy
-
Research Site
RECRUITINGMilan, 20141, Italy
-
Research Site
NOT_YET_RECRUITINGKōtoku, 135-8550, Japan
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGL'Hospitalet de Llobregat, 08908, Spain
-
Research Site
RECRUITINGMadrid, 28041, Spain
-
Research Site
RECRUITINGManchester, M20 4BX, United Kingdom
-
Research Site
RECRUITINGOxford, OX3 7LE, United Kingdom
Conditions
Explore the condition pages connected to this study.